We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK - Free Report) is joining the COVID race for the first vaccine/treatment, announcing earlier this week that it will be working towards two separate 2 vaccine efforts and 1 antiviral treatment. This pharmaceutical powerhouse will leverage its positioning with its recently acquired Themis and partnership with International Aids Vaccine Initiative (IAVI) and Ridgeback Bio.
Merck has a successful track record in vaccines, and its Themis acquisition further expands its expertise in this arena. Analysts are estimating the vaccine could boost Merck’s topline by anywhere between $2 to $5 billion, an approximately $1-2 share price impact.
Aside from its vaccine efforts, the company’s broader operations have stayed buoyant amid this pandemic. The business is currently not experiencing any production or supply issues, and demand remains strong.
MRK is down 14% for the year, and I see this as an excellent opportunity to get into this multinational pharmaceutical giant at a discount. Merck’s healthy long-term outlook and cushy 3.1% dividend make this investment quite attractive at its current price level.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Buy Merck (MRK) Stock On Vaccine Hopes
Merck (MRK - Free Report) is joining the COVID race for the first vaccine/treatment, announcing earlier this week that it will be working towards two separate 2 vaccine efforts and 1 antiviral treatment. This pharmaceutical powerhouse will leverage its positioning with its recently acquired Themis and partnership with International Aids Vaccine Initiative (IAVI) and Ridgeback Bio.
Merck has a successful track record in vaccines, and its Themis acquisition further expands its expertise in this arena. Analysts are estimating the vaccine could boost Merck’s topline by anywhere between $2 to $5 billion, an approximately $1-2 share price impact.
Aside from its vaccine efforts, the company’s broader operations have stayed buoyant amid this pandemic. The business is currently not experiencing any production or supply issues, and demand remains strong.
MRK is down 14% for the year, and I see this as an excellent opportunity to get into this multinational pharmaceutical giant at a discount. Merck’s healthy long-term outlook and cushy 3.1% dividend make this investment quite attractive at its current price level.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>